International Workshop on
Acute Leukemias (iwAL) 2021

Discussion – panellists: D. Hoelzer, S. Chiaretti, L, Muffly, N.Short, Y. Sasaki, J, Ribera

10.50 – 11.45 Session 2: CAR T-Cell | Chairs: Noelle Frey & Bijal Shah

• Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL): Peihua Lu – 159

• ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies: C.Roddie – 160

• The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: He Huang – 499

• Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement: E. Jacoby – 2798

Discussion – panellists: N.Frey, B. Shah, P.Lua, C.Roddie, H.Huang, E.Jacoby

11.45 – 12.30 Session 3: Immunotherapy | Chairs: Dan DeAngelo & Nicola Goekbucket

• First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial): N.Goekbuget – 267

• Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA): N. Goekbuget – 2795

• Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial: F. Locatelli – 268

Discussion – panellists: D.DeAngelo, N. Goekbuget, F. Locatelli, D.Hoelzer

Day 1 wrap up

Day 2 Friday 22nd, 2020 – AML

09.55 – 10.00am EST Welcome Day 2: Naval Daver/Richard Stone

10.00-10.50 Session 1: Immunotherapy | Chairs: Marion Subklewe & Bob Lowenburg

• The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results: D. Sallman – 330

• Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia: I. Aldoss – 331

• Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study: F. Ravandi – 460

• Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings: J. Garcia – 170

Discussion – panellists: M.Subklewe, B.Lowenburg, D. Sallman, I. Aldoss, F. Ravandi, J. Garcia

10.50 -11.40 Session 2: FLT3 in AML | Chairs: Naval Daver & Mark Levis

• A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results: K. Pratz – 24

• Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study: N. Daver – 333

• Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib: A. Perl – 334

• Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I Versus Type II FLT3-Inhibitors (FLT3i’s): M. Yilmaz 335

Discussion – panellists: N.Daver, M. Levis, K. Pratz, M. Yilmaz

11.40 -12.30 Session 3: Controversies in AML | Chairs: Marina Konopleva & Andrew Wei

Who should receive maintenance therapy and when?

• CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial; G. Roboz – 692

• CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial: A.Wei 1036

Should patients with pre-transplant MRD receive further pre-transplant therapy or not?

• Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia; M. Stahl – 273

Is there a role for interim BM analysis and re-induction?

• Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial: C. Rollig – 458

Discussion – panellists: M.Konopleva, A.Wei, G.Roboz, M.Stahl, C.Rollig, C.Craddock

12.30-13.30 Session 4 : Novel therapies/updates in AML & BPBCN | Chairs: Courtney DiNardo & Gail Roboz

• Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia: E. Wang 115

• Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders: J. Lancet 635

• Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML: C. Lachoweiz – 332

• Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: E. Stein 114

• Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): N. Pemmaraju 167

Discussion – panellists: C. DiNardo, G.Roboz, E.Wang, J.Lancet, C.Lachoweiz, E.Stein, N, Pemmaraju

Day 2 wrap up

End of Virtual Workshop